IntelGenx Announces Management Changes
July 15 2014 - 1:08PM
IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx")
announced today that the board of directors (the "Board") of
IntelGenx has accepted, with immediate effect, the resignation of
Dr. Rajiv Khosla as President and Chief Executive Officer ("CEO")
of IntelGenx and as a member of the Board.
Effective immediately, the Board has appointed Dr. Horst G.
Zerbe to serve as IntelGenx' interim President and CEO until a
successor is found. A Search Committee has been formed by the Board
to begin the search, selection and appointment of a new President
and CEO.
Dr. Zerbe is the Chairman of the Board, founder, and former
President and CEO of IntelGenx. He retired from the positions of
President and CEO effective December 31, 2013. However, Dr. Zerbe
retained an active role in IntelGenx' operations throughout the
past six and a half months, providing expertise in the areas of
research and development, and manufacturing.
The Board thanks Dr. Khosla for his service and contributions to
the company and wishes him well in his future endeavours
About IntelGenx:
IntelGenx is a drug delivery company focused on the development
of oral controlled-release products as well as novel rapidly
disintegrating delivery systems. IntelGenx uses its unique multiple
layer delivery system to provide zero-order release of active drugs
in the gastrointestinal tract. IntelGenx has also developed novel
delivery technologies for the rapid delivery of pharmaceutically
active substances in the oral cavity based on its experience with
rapidly disintegrating films. IntelGenx' development pipeline
includes products for the treatment of indications such as severe
depression, hypertension, erectile dysfunction, migraine, insomnia,
CNS indications, idiopathic pulmonary fibrosis, oncology and pain,
as well as animal health products. More information is available
about the company at www.intelgenx.com.
Forward-Looking Statements:
This document may contain forward-looking information about
IntelGenx' operating results and business prospects that involve
substantial risks and uncertainties. Statements that are not purely
historical are forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended, and
Section 27A of the Securities Act of 1933, as amended. These
statements include, but are not limited to, statements about
IntelGenx' plans, objectives, expectations, strategies, intentions
or other characterizations of future events or circumstances and
are generally identified by the words "may," "expects,"
"anticipates," "intends," "plans," "believes," "seeks,"
"estimates," "could," "would," and similar expressions. All forward
looking statements are expressly qualified in their entirety by
this cautionary statement. Because these forward-looking statements
are subject to a number of risks and uncertainties, IntelGenx'
actual results could differ materially from those expressed or
implied by these forward looking statements. Factors that could
cause or contribute to such differences include, but are not
limited to, those discussed under the heading "Risk Factors" in
IntelGenx' annual report on Form 10-K for the fiscal year ended
December 31, 2013, filed with the United States Securities and
Exchange Commission and available at www.sec.gov, and also filed
with Canadian securities regulatory authorities and www.sedar.com.
IntelGenx assumes no obligation to update any such forward-looking
statements.
Each of the TSX Venture Exchange and OTCQX has neither approved
nor disapproved the contents of this press release.
CONTACT: Paul A. Simmons
Chief Financial Officer
IntelGenx Technologies Corp.
T: +1 514-331-7440
F: +1 514-331-0436
www.intelgenx.com
IntelGenx Technologies (CE) (USOTC:IGXT)
Historical Stock Chart
From Aug 2024 to Sep 2024
IntelGenx Technologies (CE) (USOTC:IGXT)
Historical Stock Chart
From Sep 2023 to Sep 2024